Report period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, ₽ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Name | Issue size | Price | Yield |
---|---|---|---|
IMCB JSC BO-P01-02 (RUB) | 200,000 pcs. | 80% | 23.47% |
IMCB JSC BO-P01-01 (RUB) | 30,000 pcs. | 96.99% | 12.02% |
Date | Type | Note | Source |
---|---|---|---|
09.01.2025 10:00 | Dividends | Deadline for payment of dividends RUB 2.7 per common share for 9 month 2024. | disclosure.skrin.ru |
Company name | IMCB |
---|---|
Tags | #biotechnology, #innovations of the russia, #stem cells |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | gorod Moskva |
Mailing address | 119333, g. Moskva, ul. Gubkina, d. 3, korp. 1, etazh 1, pom. 1, komn. 24 |
CEO | Prihodko Aleksandr Viktorovich |
Phone | +7(495) 646-80-76 |
Website | invest.gemabank.ru |
Information disclosure | e-disclosure.ru |